Neurana Pharmaceuticals Inc has raised $60m in a series A financing led by Sofinnova Ventures along with participation from New Leaf Venture Partners LLC, HIG BioHealth Partners, Longitude Capital Management Co LLC, and MagnaSci Ventures.

Based in the US, Neurana Pharma is focused on the treatment of neuromuscular conditions.

The company plans to use proceeds for development of its muscle relaxant, tolperisone.

US-based BioClin Therapeutics Inc has raised a total of $50m, with a recent $20m series B financing round complete.

New investors Sectoral Asset Management Inc and INKEF Capita, along with existing investors Sofinnova Ventures Inc, Ysios Capital Partners, HealthCap Advisor AB, Life Sciences Partners BV and Tekla Capital Management LLC provided the financing.

The company plans to use proceeds for the clinical development of B-701 for the treatment of metastatic bladder cancer, or metastatic urothelial carcinoma (mUC).

Chinese company CStone Pharmaceuticals Co Ltd has raised $260m in a series B venture financing round led by GIC.

The financing round included participation from existing investors Oriza Seed Venture Capital, Boyu Capital, and 6 Dimensions Capital, as well as new investors Sequoia China, Yunfeng Capital, Taikang Insurance Group, CITIC PE, ARCH Venture Partners, Hillhouse Capital and King Star Capital.

CStone Pharmaceuticals plans to use proceeds for the expansion of its immune-oncology pipeline in China.

UK-based biopharmaceutical company Autolus Limited has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $100m through an initial public offering (IPO) of American Depositary Shares (ADSs).

Underwriters will be granted a 30-day option to buy additional shares as part of the offering.

Autolus plans to use proceeds to finance the clinical trials of its cancer treatment candidates, including AUTO1, AUTO2, AUTO3, and AUTO4. A portion of proceeds will also be used for the research and development of T-cell programming technologies and other corporate purposes.

Goldman Sachs & Co LLC, Jefferies LLC, Wells Fargo Securities LLC, and William Blair & Company LLC have been appointed as underwriters for the transaction, while Cooley LLP has been appointed as legal advisor.

Canadian clinical-stage company Xenon Pharmaceuticals Inc plans to raise $30m through a public offering of shares of its common stock.

“Synthetic Biologics Inc plans to issue securities to raise $200m.”

Xenon Pharmaceuticals plans to use proceeds for the continuation of clinical development programmes and other general corporate purposes.

The company has appointed Cooley LLP and Stifel, Nicolaus & Company Incorporated as sales agents and McCarthy Tetrault LLP as legal advisor for the transaction.

Synthetic Biologics Inc plans to issue securities to raise $200m.

The company will periodically issue securities consisting of common stock, preferred stock, debt securities, warrants and units, as part of the transaction.

Synthetic Biologics plans to use proceeds for general corporate purposes including payment of general and administrative expenses, increasing working capital, and to fund research and development, clinical trials and capital expenditures.

Gracin & Marlow, LLP and Parsons Behle & Latimer PLC have been appointed as legal advisors for the transaction.

Belgium-based contract development and manufacturing organisation (CDMO) Ardena Group has acquired Syntagon AB.

The target company is based in Sweden and involved in the production of new active pharmaceutical ingredients (APIs) and excipients.

The acquisition will help Ardena increase its drug substance manufacturing capacity to batch sizes of up to 100kg.

Eurofins Scientific SE has agreed to acquire PHAST Gesellschaft fur Pharmazeutische Qualitatsstandards mbH.

Eurofins is a provider of biopharmaceutical product testing services, while the target company is a pharmaceutical services provider. Both companies are based in Germany.

The acquisition will enable Eurofins to improve its biopharma product testing capabilities.

US company CalibreScientific Inc has acquired Protein Ark Ltd and BioServ UK Ltd.

Both target companies are UK-based and led by managing director Mike Brownleader.

Protein Ark is a contract manufacturer and services company offering a range of laboratory consumables, reagents, and custom services. BioServ UK is a specialist contract research and manufacturing organisation with expertise in the production and processing of bio-molecules.